Baseline clinical characteristic of study subjects.
| Characteristic | |
|---|---|
| Female, n (%) | 17 (68) |
| Age, months, median (range) | 40 (18–48) |
| JIA onset type, n (%) | |
| Systemic | 8 (32) |
| Oligoarticular | 12 (48) |
| Persistent | 3 (12) |
| Extended | 9 (36) |
| Polyarticular | 4 (16) |
| RF-positive | 1 (4) |
| RF-negative | 3 (12) |
| Psoriatic | 1 (4) |
| ANA-positive, n (%) | 16 (64) |
| Uveitis, n (%) | 7 (28) |
| Duration of MTX treatment before etanercept, months, median (range) | 10 (2–41) |
| Duration of disease at start of etanercept, months, median (range) | 14.2 (4–35) |
| Concurrent medication, n (%) | |
| Methotrexate | 24 (96) |
| Cyclosporine | 3 (1.6) |
| Corticosteroids | 10 (52.6) |
JIA: juvenile idiopathic arthritis; RF: rheumatoid factor; ANA: antinuclear antibody; MTX: methotrexate.